CEVR analyzes the benefits, risks, and costs of strategies to improve health and health care.

About Us
Data

News & Events

Recent Publications

Cost-effectiveness of exome and genome sequencing for children with rare and undiagnosed conditions

Genetics in Medicine

Tara A. Lavelle, Xue Feng, Marlena Keisler, Joshua T. Cohen, Peter J. Neumann, Daryl Prichard, Brock E. Schroeder, Daria Salyakina, Paula S. Espinal, Samuel B. Weidner, Jill L. Maron, Cost-effectiveness of exome and genome sequencing for children with rare and undiagnosed conditions, Genetics in Medicine, 2022, , ISSN 1098-3600, https://doi.org/10.1016/j.gim.2022.03.005.

A systematic review of economic evaluations of COVID-19 interventions: Considerations of non-health impacts and distributional issues

Value in Health

Meghan I. Podolsky, Isabel Present, Peter J. Neumann, David D. Kim, A Systematic Review of Economic Evaluations of COVID-19 Interventions: Considerations of Non-health Impacts and Distributional Issues, Value in Health, 2022, , ISSN 1098-3015, https://doi.org/10.1016/j.jval.2022.02.003.

The impact of broader value elements on cost-effectiveness analysis: Two case studies

Value in health

Siyu Ma, Natalia Olchanski, Joshua T. Cohen, Daniel A. Ollendorf, Peter J. Neumann, David D. Kim, The Impact of Broader Value Elements on Cost-Effectiveness Analysis: Two Case Studies, Value in Health, 2022, , ISSN 1098-3015, https://doi.org/10.1016/j.jval.2022.01.025.

The history and future of the “ISPOR value flower”: Addressing limitations of conventional cost-effectiveness analysis

Value in Health

Neumann PJ, Garrison LP, Willke RJ. The History and Future of the “ISPOR Value Flower”: Addressing Limitations of Conventional Cost-Effectiveness Analysis. Value in Health. 2022 March 9. DOI:https://doi.org/10.1016/j.jval.2022.01.010

Patients' access to rare neuromuscular disease therapies varies across US private insurers

Orphanet Journal of Rare Diseases

Margaretos NM, Bawa K, Engmann NJ, Chambers JD. Patients' access to rare neuromuscular disease therapies varies across US private insurers. Orphanet J Rare Dis. 2022 Feb 5;17(1):36. doi: 10.1186/s13023-022-02182-3.

The certainty of uncertainty in health technology assessment

Health Affairs Forefront

The Certainty Of Uncertainty In Health Technology Assessment, Health Affairs Forefront, January 26, 2022. DOI: 10.1377/forefront.20220125.37540

Medicare’s Aducanumab decision highlights needed reforms to FDA and CMS regulatory pathways

Health Affairs Forefront

Medicare’s Aducanumab Decision Highlights Needed Reforms To FDA And CMS Regulatory Pathways, Health Affairs Forefront, January 25, 2022. DOI: 10.1377/forefront.20220121.566837

Herd immunity effects in cost‑effectiveness analyses among low‑ and middle‑income countries

Applied Health Economics and Health Policy

Ma, S., Lavelle, T.A., Ollendorf, D.A. et al. Herd Immunity Effects in Cost-Effectiveness Analyses among Low- and Middle-Income Countries. Appl Health Econ Health Policy (2022). https://doi.org/10.1007/s40258-021-00711-y

Developmental behavioral pediatrician perspectives on decision-making in early treatment planning for children with autism spectrum disorder

Journal of Developmental and Behavioral Pediatrics

Mulé C, Sliwinski, SK, Israel R, Lavelle TA, Developmental Behavioral Pediatrician Perspectives on Decision-Making in Early Treatment Planning for Children with Autism Spectrum Disorder, Journal of Developmental & Behavioral Pediatrics: October 12, 2021 - Volume - Issue - doi: 10.1097/DBP.0000000000001002

Are medical devices cost-effective?

Applied Health Economics and Health Policy

Chambers, J.D., Silver, M.C., Berklein, F.C. et al. Are Medical Devices Cost-Effective?. Appl Health Econ Health Policy (2021). https://doi.org/10.1007/s40258-021-00698-6

Differences in the selection of health state utility values by sponsorship in published cost-effectiveness analyses

Medical Decision Making

Hendrix N, Kim DD, Patel KS, Devine B. Differences in the Selection of Health State Utility Values by Sponsorship in Published Cost-Effectiveness Analyses. Med Decis Making. 2021 Apr;41(3):366-372. doi: 10.1177/0272989X20985821. Epub 2021 Jan 15. PMID: 33451278; PMCID: PMC7987800.

Is an orphan drug's cost-effectiveness associated with US health plan coverage restrictiveness?

PharmaoEconomics

Chambers JD, Margaretos NM, Enright DE, Wang R, Ye X. Is an Orphan Drug's Cost-Effectiveness Associated with US Health Plan Coverage Restrictiveness? Pharmacoeconomics. 2021 Oct 26. doi: 10.1007/s40273-021-01096-5

Frequency and impact of the inclusion of broader measures of value in economic evaluations of vaccines

Vaccine

Madison C. Silver, Peter J. Neumann, Siyu Ma, David D. Kim, Joshua T. Cohen, Mawuli Nyaku, Craig Roberts, Anushua Sinha, Daniel A. Ollendorf, Frequency and impact of the inclusion of broader measures of value in economic evaluations of vaccines, Vaccine, 2021,

Variation in access to hemophilia A treatments in the United States

Journal of Medical Economics

Margaretos NM, Patel AM, Panzer AD, Lai RC, Whiteley J, Chambers JD. Variation in access to hemophilia A treatments in the United States. J Med Econ. 2021 Jan-Dec;24(1):1143-1148

Valuing Alzheimer disease therapies—Considering costs and benefits beyond the patient

JAMA Network Open

Lin P, Neumann PJ. Valuing Alzheimer Disease Therapies—Considering Costs and Benefits Beyond the Patient. JAMA Netw Open. 2021;4(10):e2131913. doi:10.1001/jamanetworkopen.2021.31913

The CEVR Team

Our team of experienced, dedicated researchers is led by health economists Peter Neumann and Josh Cohen. Together we produce cutting-edge health care cost-effectiveness research.

Meet the CEVR Team

Our Databases

Our comprehensive databases provide the information individuals and organizations need to analyze the benefits, risks, and costs of strategies to improve health and health care.